Desai, Nihar R.
Campbell, Caresse
Electricwala, Batul
Petrou, Margaret http://orcid.org/0000-0002-0161-7980
Trueman, David
Woodcock, Fionn
Cristino, Joaquim
Funding for this research was provided by:
Novartis Pharmaceuticals Corporation
Article History
Accepted: 13 March 2022
First Online: 21 May 2022
Declarations
:
: This study was funded by Novartis Pharmaceuticals Corporation, USA
: Caresse Campbell, Batul Electricwala, and Joaquim Cristino are employees of Novartis Pharmaceuticals Corporation, USA, and shareholders of Novartis Pharmaceuticals Corporation stock. Nihar R. Desai is an employee of Yale University School of Medicine and works under contract with the Centers for Medicare and Medicaid Services to develop and maintain performance measures used for public reporting and pay-for-performance programs. Nihar R. Desai also reports research grants and consulting for Amgen, Astra Zeneca, Boehringer Ingelheim, Cytokinetics, MyoKardia, Relypsa, Novartis, and scPharmaceuticals. Margaret Petrou, David Trueman, and Fionn Woodcock are employees of Source Health Economics, UK, the health economics and outcomes research (HEOR) company that conducted the cost-effectiveness analysis and provided writing services. Work by Source Health Economics was funded by Novartis. Inclisiran, sold under the brand name Leqvio<sup>®</sup>, has been developed by Novartis and is approved in Europe for lowering LDL-cholesterol levels in patients with hypercholesterolemia or mixed dyslipidemia. The efficacy and safety of inclisiran has been evaluated in the ORION clinical trial program; ORION clinical trials cited in this manuscript were developed and funded by Novartis. Caresse Campbell and Margaret Petrou had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
: All data generated or analyzed during this study are included in this published article (and its supplementary information files).
: Not required for this study. Methods for the economic evaluation were evaluated against the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist.
: Not applicable.
: Not applicable.
: Not applicable.